Ipragliflozin
- Generic Name
- Ipragliflozin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21FO5S
- CAS Number
- 761423-87-4
- Unique Ingredient Identifier
- 3N2N8OOR7X
- Background
Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 262
- Registration Number
- NCT02175784
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 174
- Registration Number
- NCT01672762
Drug to Drug Interaction Study With Ipragliflozin and Furosemide
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 24
- Registration Number
- NCT01611415
Absolute Bioavailability Study With Ipragliflozin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT01611428
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 122
- Registration Number
- NCT01316107
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 113
- Registration Number
- NCT01242202
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 106
- Registration Number
- NCT01242228
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 152
- Registration Number
- NCT01225081
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 168
- Registration Number
- NCT01135433
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 343
- Registration Number
- NCT01117584
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath